Edition:
India

Qiagen NV (QIA.DE)

QIA.DE on Xetra

30.42EUR
23 May 2018
Change (% chg)

€0.07 (+0.23%)
Prev Close
€30.35
Open
€30.30
Day's High
€30.47
Day's Low
€30.13
Volume
242,397
Avg. Vol
499,744
52-wk High
€31.52
52-wk Low
€25.22

Latest Key Developments (Source: Significant Developments)

HTG Molecular Diagnostics Inc Says On March 30, 2018, Co And Qiagen Manchester Limited Entered Second Amendment Of First Statement Of Work
Thursday, 5 Apr 2018 

April 5 (Reuters) - HTG Molecular Diagnostics Inc :HTG MOLECULAR DIAGNOSTICS INC - ON MARCH 30, 2018, CO AND QIAGEN MANCHESTER LIMITED ENTERED SECOND AMENDMENT OF FIRST STATEMENT OF WORK - SEC FILING.HTG MOLECULAR DIAGNOSTICS INC - QIAGEN HAS AGREED TO PAY COMPANY LOW, SINGLE-DIGIT MILLIONS OF DOLLARS IN DEVELOPMENT FEES FOR NEXT-PHASE ACTIVITIES.HTG- QIAGEN ALSO AGREED TO PAY CO MILESTONE UPTO AMOUNT IN LOW,SINGLE-DIGIT MLN OF DOLLARS ON ACHIEVEMENT OF SOME MILESTONES IN NEXT-PHASE ACTIVITIES.HTG MOLECULAR DIAGNOSTICS INC - THE NEXT-PHASE ACTIVITIES ARE EXPECTED TO BE COMPLETED IN Q2 OF 2018.  Full Article

Qiagen Q4 Loss Per Share $0.18 Including Items
Thursday, 1 Feb 2018 

Jan 31 (Reuters) - Qiagen Nv ::QIAGEN REPORTS RESULTS FOR FOURTH QUARTER AND FULL-YEAR 2017, ANNOUNCES STAT-DX ACQUISITION AND NEW $200 MILLION SHARE REPURCHASE.Q4 SALES ROSE 8 PERCENT TO $396.9 MILLION.Q4 LOSS PER SHARE $0.18 INCLUDING ITEMS.Q4 ADJUSTED EARNINGS PER SHARE $0.43.REAFFIRMS 2020 MID-TERM TARGETS.Q4 EARNINGS PER SHARE VIEW $0.40 -- THOMSON REUTERS I/B/E/S.FOR 2018, EXPECTS UNDERLYING GROWTH IN ADJUSTED EARNINGS PER SHARE TO BE APPROXIMATELY $1.38-$1.40 CER.FOR 2018, QIAGEN EXPECTS UNDERLYING GROWTH IN ADJUSTED EARNINGS PER SHARE EXPECTED TO BE REDUCED TO ABOUT $1.31-1.33 CER.ORGANIC GROWTH IN NET SALES IS EXPECTED TO BE ABOUT 6-7% CER FOR 2018.  Full Article

Qiagen Signs Agreement To Acquire Stat-Dx
Thursday, 1 Feb 2018 

Jan 31 (Reuters) - Qiagen Nv ::QIAGEN ENTERS INTO AGREEMENT TO ACQUIRE STAT-DX, PLANS TO LAUNCH A NEXT-GENERATION, FULLY INTEGRATED MULTIPLEX PLATFORM FOR SYNDROMIC DISEASE TESTING.QIAGEN NV - NEW SYSTEM LAUNCH PLANNED FOR H2 2018 WITH TWO CE-IVD MOLECULAR DIAGNOSTICS, U.S. LAUNCH PLANNED FOR 2019.  Full Article

Facebook Reports Qtrly Earnings Per Share $1.44
Thursday, 1 Feb 2018 

Jan 31 (Reuters) - Facebook Inc ::FACEBOOK REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS.QTRLY EARNINGS PER SHARE $1.44.QTRLY TOTAL REVENUE $12,972 MILLION VERSUS $8,809 MILLION.DAUS WERE 1.40 BILLION ON AVERAGE FOR DECEMBER 2017, AN INCREASE OF 14% YEAR-OVER-YEAR‍​.MAUS WERE 2.13 BILLION AS OF DECEMBER 31, 2017, AN INCREASE OF 14% YEAR-OVER-YEAR.QTRLY ADVERTISING REVENUE $12,779 MILLION VERSUS $8,629 MILLION.HEADCOUNT WAS 25,105 AS OF DECEMBER 31, 2017, AN INCREASE OF 47% YEAR-OVER-YEAR‍​.QTRLY OPERATING MARGIN 57 PERCENT VERSUS 52 PERCENT.FACEBOOK - MADE CHANGES IN QUARTER THAT REDUCED TIME SPENT ON FACEBOOK BY ROUGHLY 50 MILLION HOURS EVERY DAY.AS A RESULT OF TAX LAW, PROVISION FOR INCOME TAXES INCREASED BY $2.27 BILLION,DILUTED EPS DECREASED BY $0.77 FOR Q4, FULL YEAR 2017‍​.FACEBOOK - MOBILE ADVERTISING REVENUE REPRESENTED ABOUT 89% OF ADVERTISING REVENUE FOR Q4 2017, UP FROM ABOUT 84% OF ADVERTISING REVENUE IN Q4 2016.Q4 EARNINGS PER SHARE VIEW $1.95, REVENUE VIEW $12.55 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Qiagen to exceed $140 mln of NGS-related sales In 2018
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Qiagen Nv ::SAYS ‍GOAL SET TO EXCEED $140 MILLION OF NGS-RELATED SALES IN 2018, UP FROM OVER $115 MILLION IN 2017​.  Full Article

Qiagen, DiaSorin partner in automated tuberculosis detection
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Qiagen Nv ::SAYS ‍QIAGEN AND DIASORIN PARTNER TO OFFER FULLY AUTOMATED TUBERCULOSIS DETECTION WITH QUANTIFERON-TB GOLD PLUS AVAILABLE ON LIAISON ANALYZER SYSTEMS​.SAYS ‍DIASORIN TO ADD NOVEL CONTENT TO ALREADY BROAD LIAISON MENU, OVER 7,000 SYSTEMS INSTALLED​.SAYS ‍ANNOUNCES MILESTONE OF OVER 40 MILLION QUANTIFERON-TB TESTS SINCE LAUNCH​.  Full Article

Diasorin And Qiagen Partner To Offer Fully Automated Solution For Diagnosis Of Tuberculosis
Monday, 8 Jan 2018 

Jan 8 (Reuters) - DIASORIN SPA ::ANNOUNCES PARTNERSHIP WITH QIAGEN TO OFFER FULLY AUTOMATED SOLUTION FOR DIAGNOSIS OF TUBERCULOSIS.UNDER AGREEMENT, PARTIES ARE DEVELOPING FULLY AUTOMATED VERSION OF QUANTIFERON TEST READ-OUT COMPONENTS.  Full Article

Qiagen To Take Impairment On Deferred Tax Assets
Saturday, 23 Dec 2017 

Dec 22 (Reuters) - Qiagen NV ::QIAGEN TO TAKE IMPAIRMENT ON DEFERRED TAX ASSETS, INFORMS ON EXPECTED IMPACTS OF NEW U.S. TAX LAW AND OTHER CHANGES IN GLOBAL TAX ENVIRONMENT.QIAGEN - WILL TAKE AN AFTER-TAX CHARGE ON NET INCOME OF ABOUT $110 MILLION-$120 MILLION (OR ABOUT $0.47-$0.52 PER SHARE) IN Q4.QIAGEN NV - WILL TAKE ADDITIONAL AFTER-TAX CHARGE IN 2018 OF ABOUT $7 MILLION (OR ABOUT $0.03 PER SHARE).  Full Article

‍Qiagen says it ‍will Take Extraordinary After-Tax Charge On Net Income Of About $110-120 mln In Q4 2017 Due To US Tax Reform
Saturday, 23 Dec 2017 

Dec 22 (Reuters) - Qiagen Nv ::‍QIAGEN TO TAKE IMPAIRMENT ON DEFERRED TAX ASSETS, INFORMS ON EXPECTED IMPACTS OF NEW U.S. TAX LAW AND OTHER CHANGES IN GLOBAL TAX ENVIRONMENT​.DUE TO US TAX REFORM ‍WILL TAKE EXTRAORDINARY AFTER-TAX CHARGE ON NET INCOME OF ABOUT $110-120 MILLION IN Q4 OF 2017​.WILL ALSO TAKE ‍AN ADDITIONAL EXTRAORDINARY AFTER-TAX CHARGE IN 2018 OF APPROXIMATELY $7 MILLION (OR ABOUT $0.03 PER SHARE)​.‍AS A RESULT, A NEW AFTER-TAX CHARGE OF APPROXIMATELY $10 MILLION IS PLANNED TO BE TAKEN IN Q4 OF 2017​.SAYS ‍DOES NOT EXPECT ANY ADDITIONAL MATERIAL NON-M&A RELATED RESTRUCTURING CHARGES IN 2018​.‍DO NOT AFFECT QIAGEN'S ADJUSTED EPS FORECAST FOR Q4 AND FULL-YEAR 2018.CURRENTLY EXPECTS A PRELIMINARY ADJUSTED TAX RATE FOR FULL-YEAR 2018 OF APPROXIMATELY 20-21%.‍EXTRAORDINARY COSTS WILL BE EXCLUDED FROM ADJUSTED RESULTS​.  Full Article

HTG Molecular Diagnostics And Unit Of QIAGEN Amended First Statement Of Work Under Master Agreement
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Htg Molecular Diagnostics Inc ::HTG MOLECULAR DIAGNOSTICS - ON DEC. 18. CO, UNIT OF QIAGEN, AMENDED FIRST STATEMENT OF WORK UNDER MASTER AGREEMENT - SEC FILING.HTG MOLECULAR DIAGNOSTICS - UNDER AGREEMENT, QIAGEN AGREED TO PAY CO LOW, SINGLE‑DIGIT MILLIONS OF DOLLARS FOR NEXT‑PHASE ACTIVITIES FOR PROJECT.  Full Article